Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) and Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT) is the only curative option for many patients with relapsed or refractory nonHodgkin's lymphoma. Several prospective randomized studies have documented the superiority of APBSCT over salvage chemotherapy in patients with relapsed lymphomas. However the role of APBSCT as an upfront therapy for patients with high-risk lymphomas remains unclear. In Japan, there are a few consensuses which patient with lymphoma is adapted by APBSCT and Allo HSCT, so we introduce them.

